Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Akwụsịla nnwale I-Spy COVID maka ọrịa siri ike: enweghị mmetụta buru ibu

Taa, Quantum Leap Healthcare Collaborative (QLHC), onye na-akwado I-SPY COVID Trial, kwupụtara na akwụsịla ogwe aka IC14 nke ikpe ahụ. Mkpebi a bụ n'ihi ohere dị elu na IC14 agaghị enwe nnukwu mmetụta na mbelata oge mgbake ma ọ bụ ọnwụ na ndị ọrịa nwere COVID-19 siri ike.

Print Friendly, PDF & Email

IC14 bụ ihe mgbochi chimeric monoclonal nke ahọpụtara maka nsonye na nnwale ahụ n'ihi na ịchụ CD14 nwere ike ịbụ atụmatụ dabara adaba iji gbanwee nzaghachi mgbochi ọrịa ebumpụta ụwa nke na-ebute ọrịa siri ike na mmebi akụkụ ahụ na ọrịa COVID-19. Akwụsịrị ule nke IC14 na nkwenye nke Kọmitii Nleba anya Data (DMC) mgbe isiokwu 66 na-edobe na ogwe aka IC14 ma nyochaa n'ime ọnụ ọgụgụ Intent-to-Treat (ITT). Ndị ọrịa e kenyere ogwe aka IC14 natara ọgwụgwọ ọkpụkpụ azụ, gụnyere dexamethasone na remdesivir, gbakwunyere 4 mg/kg nke IC14 site na infusion intravenous na ụbọchị 1 na 2 mg / kg na ụbọchị 2, 3 na 4.

Atụnyere nsonaazụ IC14 ka isiokwu iri asaa na isii bụ ndị echekwabara n'otu oge na ogwe njikwa azụ. Ezuzughị ụkpụrụ ngụsị akwụkwọ, mana usoro nke enweghị isi bụ nke ezutere n'akụkụ ụfọdụ. Ihe gbasara nke puru omume na IC76 nwere ike ibelata oge iji nwetaghachi 14%; ihe gbasara nke puru omume na ogwe aka IC3.4 dị elu karịa ogwe aka na-ejikọta ọnụ iji belata ọnwụ bụ 14%. Mgbe ndị ọrịa niile rutere ụbọchị 62 nke nleba anya, data ahụ na-atụ aro na enwere ohere dị ala na mgbakwunye nke IC28 na ọgwụgwọ ọkpụkpụ azụ ga-enwe mmetụta na oge mgbake ma ọ bụ ọnwụ.

Emebere nnwale I-SPY COVID ka ndị ọrụ nyocha ngwa ngwa gosipụtara nkwa maka ibelata oge mgbake (akọwapụtara dị ka mbelata nke ọchịchọ oxygen) ma ọ bụ ihe egwu nke ịnwụ na ndị ọrịa COVID-19 siri ike. Ọmụmụ ihe a na-eji usoro nhazi usoro nnwale ikpo okwu QLHC, nke na-elekwasị anya n'otu oge, ntule dị mma nke ọtụtụ ndị ọrụ nyocha. Ndị nnọchi anya gara aga nyochara na nnwale ahụ gụnyere cenicriviroc, razuprotafib, apremilast, icatibant na famotidine gbakwunyere celecoxib. A na-atụ aro ogwe aka onye ọrụ nyocha maka nkwụsị n'ihi ihe efu ma ọ bụrụ na enweghi nkwalite zuru oke na mgbake ma ọ bụ ọnwụ. Kpọmkwem, iwu enweghị isi ndị a metụtara:

1. Ọgwụgwọ na-agafe 90% nke puru omume na ọnụ ọgụgụ ihe ize ndụ maka uru na oge mgbake bụ ihe na-erughị 1.5 ma e jiri ya tụnyere ọgwụgwọ ọkọlọtọ (Pr (HR <1.5) ≥ 0.9)

2. Ihe gbasara nke puru omume maka oke ihe egwu ya maka onwu n'ozuzu ya vs. azu (doziri maka ọkwa COVID-19 na ntọala) karịrị otu karịrị ma ọ bụ ha nhata 0.5 (Pr (HRmortality> 1) ≥ 0.5).

A na-elekọta IC14 na saịtị US 24 na-ekere òkè. Enweghị nsogbu nchekwa metụtara IC14 na nnwale ahụ.

Nnyocha n'ime ndị ọrụ ndị ọzọ site na I-SPY COVID Trial na-aga n'ihu, ndị nyocha ahụ na-aga n'ihu na-enyocha ọgwụgwọ ngwa ngwa iji chọpụta ọgwụgwọ ọgwụgwọ dị irè; nke a ka bụ ihe kacha mkpa maka QLHC na ndị mmekọ ya. Ọnwụnwa COVID I-SPY ugbu a gụnyere saịtị 24 yana ndị isi na ụlọ ọrụ nlekọta akpa ume na nke siri ike sitere na mba ahụ.

Ọnwụnwa COVID I-SPY bụ mmekorita n'etiti ndị otu Quantum Leap, ndị mmekọ ọgwụ dịka implicit Bioscience na gọọmentị United States. Ọrụ a na-akwado akụkụ nke Biomedical Advanced Research and Development Authority (BARDA), akụkụ nke ụlọ ọrụ nke odeakwụkwọ enyemaka maka nkwadebe na nzaghachi n'ime Ngalaba Ahụike na Ọrụ Ndị Ọrụ US, yana Ngalaba Defence Joint Program Executive Office maka Chemical, Biological, Radiological and Nuclear Defense, na mmekorita ya na Medical, Chemical, Biological, Radiological and Nuuclear (CBRN) Defence Consortium (MCDC) - (nkwekọrịta MCDC2014-001). Ụlọ ọrụ Defence Threat Reduction Agency (DTRA) na-enyere Ngalaba Nchebe (DoD), Gọọmenti US, na Ndị Mmekọ Mba Nile aka igbochi na igbochi Ngwá Agha nke mbibi Mass (WMD) na egwu na-apụta.

Print Friendly, PDF & Email

Banyere chepụtara

Linda Hohnholz, onye editọ eTN

Linda Hohnholz na-ede ma na-edezi isiokwu kemgbe ọ malitere ọrụ ya. O tinyela obi uto nke a dika ebe Hawaii Pacific University, Chaminade University, Hawaii Discovery Center, ma ugbu a TravelNewsGroup.

Ahapụ a Comment